Silence Therapeutics (SLNCF) Total Current Liabilities (2019 - 2025)
Historic Total Current Liabilities for Silence Therapeutics (SLNCF) over the last 7 years, with Q3 2025 value amounting to $17.4 million.
- Silence Therapeutics' Total Current Liabilities rose 17908.51% to $17.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.4 million, marking a year-over-year increase of 17908.51%. This contributed to the annual value of $16.8 million for FY2024, which is 2468.66% down from last year.
- As of Q3 2025, Silence Therapeutics' Total Current Liabilities stood at $17.4 million, which was up 17908.51% from $14.8 million recorded in Q2 2025.
- Silence Therapeutics' Total Current Liabilities' 5-year high stood at $25.7 million during Q4 2022, with a 5-year trough of -$30.6 million in Q3 2022.
- Its 5-year average for Total Current Liabilities is -$9.0 million, with a median of -$21.3 million in 2023.
- Per our database at Business Quant, Silence Therapeutics' Total Current Liabilities plummeted by 18568.81% in 2023 and then soared by 20712.63% in 2025.
- Over the past 5 years, Silence Therapeutics' Total Current Liabilities (Quarter) stood at $20.4 million in 2021, then increased by 25.89% to $25.7 million in 2022, then crashed by 185.69% to -$22.1 million in 2023, then surged by 176.28% to $16.8 million in 2024, then increased by 3.31% to $17.4 million in 2025.
- Its Total Current Liabilities stands at $17.4 million for Q3 2025, versus $14.8 million for Q2 2025 and $19.3 million for Q1 2025.